SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...
SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.
Global VICTORIA-01 Phase 1 study evaluating safety and efficacy of SOT201 in advanced solid tumor patients currently enrolling; SOTIO Biotech, a clinical-stage immuno-oncology company owned by ...
SOTIO’s immunocytokine platform is designed to preferentially activate immune cells in the tumor microenvironment by targeted delivery of a cytokine agonist.
SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment.
SOTIO’s proprietary antibody-drug conjugate (ADC) platform yields potent and highly stable ADCs with a wide therapeutic window for the treatment of cancer …